Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography with gallium-67 scintigraphy in the initial clinical staging of diffuse large B-cell lymphoma

Masatoshi Sakurai, Takaaki Toyama, Taku Kikuchi, Jun Kato, Takayuki Shimizu, Yuya Koda, Daiki Karigane, Yusuke Yamane, Ryohei Abe, Rie Yamazaki, Tomonori Nakazato, Tadaki Nakahara, Masahiro Jinzaki, Shinichiro Okamoto, Takehiko Mori

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) has been recommended as a complementary tool for the staging of various malignancies, including malignant lymphoma. PET findings often shift patients to higher stages and may affect treatment outcomes. In this study, we retrospectively compared staging and treatment outcomes of newly diagnosed diffuse large B-cell lymphoma (DLBCL) assessed by PET (n = 153) or gallium-67 scintigraphy (Ga) (n = 95). In total, Ga upstaged two (2.1%) of 95 patients, whereas PET upstaged 13 (8.5%) of 153 patients. Bone/bone marrow (15 vs. 4%, P = 0.01) and muscle lesion (5 vs. 0%, P = 0.03) were identified more frequently in the PET group than in the Ga group. The estimated 3-year overall and progression-free survival rates did not differ significantly in the two groups at any stage. However, patients with stage III disease tended to have better progression-free survival in the PET group than in the Ga group [92.3 (95% CI 56.6–98.9%) vs. 58.3% (95% CI 27.0–80.1%), P = 0.086]. These results suggest that PET has a greater potential in detecting musculoskeletal lesions of DLBCL as extranodal lesions than Ga, and may contribute to the optimal staging.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalInternational Journal of Hematology
DOIs
Publication statusAccepted/In press - 2017 Oct 9

Fingerprint

Gallium
Lymphoma, Large B-Cell, Diffuse
Fluorodeoxyglucose F18
Radionuclide Imaging
Positron-Emission Tomography
Disease-Free Survival
Lymphoma
Survival Rate
Bone Marrow
Bone and Bones
Muscles

Keywords

  • Diffuse large B-cell lymphoma
  • Gallium scintigraphy
  • Positron emission tomography
  • Staging

ASJC Scopus subject areas

  • Hematology

Cite this

@article{591fdbbc74794b239ee34fca60472252,
title = "Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography with gallium-67 scintigraphy in the initial clinical staging of diffuse large B-cell lymphoma",
abstract = "Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) has been recommended as a complementary tool for the staging of various malignancies, including malignant lymphoma. PET findings often shift patients to higher stages and may affect treatment outcomes. In this study, we retrospectively compared staging and treatment outcomes of newly diagnosed diffuse large B-cell lymphoma (DLBCL) assessed by PET (n = 153) or gallium-67 scintigraphy (Ga) (n = 95). In total, Ga upstaged two (2.1{\%}) of 95 patients, whereas PET upstaged 13 (8.5{\%}) of 153 patients. Bone/bone marrow (15 vs. 4{\%}, P = 0.01) and muscle lesion (5 vs. 0{\%}, P = 0.03) were identified more frequently in the PET group than in the Ga group. The estimated 3-year overall and progression-free survival rates did not differ significantly in the two groups at any stage. However, patients with stage III disease tended to have better progression-free survival in the PET group than in the Ga group [92.3 (95{\%} CI 56.6–98.9{\%}) vs. 58.3{\%} (95{\%} CI 27.0–80.1{\%}), P = 0.086]. These results suggest that PET has a greater potential in detecting musculoskeletal lesions of DLBCL as extranodal lesions than Ga, and may contribute to the optimal staging.",
keywords = "Diffuse large B-cell lymphoma, Gallium scintigraphy, Positron emission tomography, Staging",
author = "Masatoshi Sakurai and Takaaki Toyama and Taku Kikuchi and Jun Kato and Takayuki Shimizu and Yuya Koda and Daiki Karigane and Yusuke Yamane and Ryohei Abe and Rie Yamazaki and Tomonori Nakazato and Tadaki Nakahara and Masahiro Jinzaki and Shinichiro Okamoto and Takehiko Mori",
year = "2017",
month = "10",
day = "9",
doi = "10.1007/s12185-017-2337-7",
language = "English",
pages = "1--7",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography with gallium-67 scintigraphy in the initial clinical staging of diffuse large B-cell lymphoma

AU - Sakurai, Masatoshi

AU - Toyama, Takaaki

AU - Kikuchi, Taku

AU - Kato, Jun

AU - Shimizu, Takayuki

AU - Koda, Yuya

AU - Karigane, Daiki

AU - Yamane, Yusuke

AU - Abe, Ryohei

AU - Yamazaki, Rie

AU - Nakazato, Tomonori

AU - Nakahara, Tadaki

AU - Jinzaki, Masahiro

AU - Okamoto, Shinichiro

AU - Mori, Takehiko

PY - 2017/10/9

Y1 - 2017/10/9

N2 - Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) has been recommended as a complementary tool for the staging of various malignancies, including malignant lymphoma. PET findings often shift patients to higher stages and may affect treatment outcomes. In this study, we retrospectively compared staging and treatment outcomes of newly diagnosed diffuse large B-cell lymphoma (DLBCL) assessed by PET (n = 153) or gallium-67 scintigraphy (Ga) (n = 95). In total, Ga upstaged two (2.1%) of 95 patients, whereas PET upstaged 13 (8.5%) of 153 patients. Bone/bone marrow (15 vs. 4%, P = 0.01) and muscle lesion (5 vs. 0%, P = 0.03) were identified more frequently in the PET group than in the Ga group. The estimated 3-year overall and progression-free survival rates did not differ significantly in the two groups at any stage. However, patients with stage III disease tended to have better progression-free survival in the PET group than in the Ga group [92.3 (95% CI 56.6–98.9%) vs. 58.3% (95% CI 27.0–80.1%), P = 0.086]. These results suggest that PET has a greater potential in detecting musculoskeletal lesions of DLBCL as extranodal lesions than Ga, and may contribute to the optimal staging.

AB - Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) has been recommended as a complementary tool for the staging of various malignancies, including malignant lymphoma. PET findings often shift patients to higher stages and may affect treatment outcomes. In this study, we retrospectively compared staging and treatment outcomes of newly diagnosed diffuse large B-cell lymphoma (DLBCL) assessed by PET (n = 153) or gallium-67 scintigraphy (Ga) (n = 95). In total, Ga upstaged two (2.1%) of 95 patients, whereas PET upstaged 13 (8.5%) of 153 patients. Bone/bone marrow (15 vs. 4%, P = 0.01) and muscle lesion (5 vs. 0%, P = 0.03) were identified more frequently in the PET group than in the Ga group. The estimated 3-year overall and progression-free survival rates did not differ significantly in the two groups at any stage. However, patients with stage III disease tended to have better progression-free survival in the PET group than in the Ga group [92.3 (95% CI 56.6–98.9%) vs. 58.3% (95% CI 27.0–80.1%), P = 0.086]. These results suggest that PET has a greater potential in detecting musculoskeletal lesions of DLBCL as extranodal lesions than Ga, and may contribute to the optimal staging.

KW - Diffuse large B-cell lymphoma

KW - Gallium scintigraphy

KW - Positron emission tomography

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=85030833032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030833032&partnerID=8YFLogxK

U2 - 10.1007/s12185-017-2337-7

DO - 10.1007/s12185-017-2337-7

M3 - Article

SP - 1

EP - 7

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

ER -